Gary M. Owens, MD

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective

ByGary M. Owens, MD

March 31st 2014

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Participating Faculty: Improving Transitions of Care for Patients With Thromboembolic Disease

ByGary M. Owens, MD,Claudia Fine, MSW, MPH,Darrell W. Harrington, MD,Alan K. Jacobson, MD, FACC,Geno J. Merli, MD,Edith Nutescu, PharmD, FCCP,Kenneth L. Schaecher, MD, FACP, CPC,Jacqueline Vance,

March 21st 2014

Improving Transitions of Care for Patients With Thromboembolic Disease

ByGary M. Owens, MD,Claudia Fine, MSW, MPH,Darrell W. Harrington, MD,Alan K. Jacobson, MD, FACC,Geno J. Merli, MD,Edith Nutescu, PharmD, FCCP,Kenneth L. Schaecher, MD, FACP, CPC,Jacqueline Vance,

March 20th 2014

Managed Care Aspects of Managing Multiple Sclerosis

ByGary M. Owens, MD

November 26th 2013

Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

ByRobert Navarro, PharmD,Jeffrey D. Dunn, PharmD, MBA,Peter A. Lee, MD, PhD,Gary M. Owens, MD,Robert Rapaport, MD

November 24th 2013

The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases

ByGary M. Owens, MD

July 3rd 2013

Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.

Latest Updated Articles

Rethinking Heart Failure: Patient Classification and Treatment
November 10th 2022
The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases
July 3rd 2013
Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective
March 31st 2014
Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers
March 31st 2014
New FDA Guidance on Biosimilars: Another Step Forward A Payer Perspective
May 30th 2014
Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape
January 1st 2015

Gary M. Owens, MD

Articles by Gary M. Owens, MD

Participating Faculty: Rethinking Heart Failure: Patient Classification and Treatment

Rethinking Heart Failure: Patient Classification and Treatment

The Spectrum of Progressive Fibrosing Interstitial Lung Disease: Clinical and Managed Care Considerations

Systemic Sclerosis With Associated Interstitial Lung Disease: Management Considerations and Future Directions

Idiopathic Pulmonary Fibrosis: Exploring the Clinical and Economic Implications of the Evolving Treatment Landscape

The Economic Burden and Managed Care Implications of Chronic Inflammatory Demyelinating Polyneuropathy

Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-The New and Evolving Standards of Care

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape

Managed Care Implications in Managing Rheumatoid Arthritis

New FDA Guidance on Biosimilars: Another Step Forward A Payer Perspective

Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers

Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective

Participating Faculty: Improving Transitions of Care for Patients With Thromboembolic Disease

Improving Transitions of Care for Patients With Thromboembolic Disease

Managed Care Aspects of Managing Multiple Sclerosis

Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases

Successful Aging in Men with BPH

Migraine in the Managed Care Environment

Clinician and Payer Issues in Managing Growth Hormone Deficiency

Latest Updated Articles

Trending on AJMC

Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD